Results 91 to 100 of about 87,310 (290)
Production test IP-466-A test of the 190 turbine pumps at KE(KW) Rector (Project CGI-844)
Stephen S. Jones
openalex +2 more sources
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva+5 more
wiley +1 more source
The Tree in the Projective Tests
Yong-Long Tang+3 more
openaire +2 more sources
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef+10 more
wiley +1 more source
Review of a projected 1/12 segment reflector test
James Chi, John Ferris
openalex +2 more sources
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo+11 more
wiley +1 more source
CURRENT STATUS OF PROJECTIVE TEST THEORIES AND PROJECTIVE TECHNIQUES
Gordon F. Derner
openalex +2 more sources
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková+14 more
wiley +1 more source